Target intelligence / Profile preview

Acyl-coenzyme A synthetase 10 (ACSL10)

Target
ACSL10
Molecular classification
Enzyme, Ligase, Fatty acid activating enzyme
01

Overview

Acyl-coenzyme A synthetases (ACSs) are a superfamily of enzymes that catalyze the thioesterification of free fatty acids with coenzyme A, converting fatty acids into their active acyl-CoA forms. This reaction is essential for channeling fatty acids into metabolic pathways, including β-oxidation for energy generation and biosynthesis of complex lipids. There are at least 26 mammalian ACS isoforms, with ACSL10 and the related ACSL11 belonging to the long-chain family, activating C12–C20 fatty acids. These enzymes play central roles in cellular lipid homeostasis and are implicated in a variety of diseases involving energy metabolism, including cancer, cardiovascular disease, and neurodegenerative diseases. They are considered potential therapeutic targets in these conditions due to their regulatory roles in lipid handling. The precise functions of individual isoforms (including ACSL10 and ACSL11) may vary by tissue and substrate specificity, and redundancy can complicate their biological assignment[1][2][3][4][5].

Other names
Acyl-coenzyme A synthetase family member 10Long-chain acyl-CoA synthetase 10ACSL10
02

Mechanism of action

Activation of free long-chain fatty acids by CoA thioesterification, committing them to anabolic (lipid synthesis) or catabolic (β-oxidation) pathways[1][3][4]. Drugs (experimental) could act as inhibitors by blocking fatty acid activation or downstream lipid metabolism.

03

Biological functions

Fatty acid metabolismActivation of long-chain fatty acidsLipid biosynthesisEnergy production/cellular energy homeostasisLipid membrane remodeling
04

Disease associations

CancerCardiovascular diseaseNeurodegenerative diseaseMetabolic disordersOther (roles in general metabolism & metabolic regulation)
05

Safety considerations

Disruption/inhibition may broadly affect energy metabolism, fatty acid homeostasis, and membrane lipid composition[1].Systemic inhibition could result in metabolic toxicity or organ-specific side effects, though specific clinical safety concerns for ACSL10/11 are not established.
06

Biomarkers

Altered expression of ACSL family members (including ACSL10, ACSL11) may serve as a biomarker for cancer/metabolic disease progression[2][4].

Beyond the preview

Go deeper on Acyl-coenzyme A synthetase 10 (ACSL10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acyl-coenzyme A synthetase 10 (ACSL10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call